LFT slightly high. There is no pain. No yellowing of the eyes. No weakness. So it is easy to brush it aside. But the liver ...
Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus Initiation of Phase 1 Clinical Program Anticipated ...
GSK’s bepirovirsen accepted for regulatory review in Japan as a potential first-in-class treatment for chronic hepatitis B: London, UK Friday, February 27, 2026, 09:00 Hrs [IST] ...
Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus Initiation of Phase 1 Clinical Program Anticipated Mid-2026 BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuti ...
Studies show that up to 50% of patients may experience recurrence within two to three years after curative surgery. By five ...
Doctors say that fatty liver disease has become a leading indication for transplantation in India.
FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...
MedPage Today on MSN
Novel Two-Drug Combo Equals Standard Triplet in Untreated Patients With HIV
The doravirine and islatravir pair could offer an alternative to INSTI-based treatment opt ...
Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and ...
EMBRACE reported 12-month suppression rates of 94% (IV N6LS+CAB LA), 82% (SC), and 88% (oral SOC), with no virologic failures and no new clinically significant AEs after month 6. Presentations focused ...
According to one analyst, the alliance and early data “validate” the oncology work of Vir, which was once purely an ...
MedPage Today on MSN
Single-Tablet Combo Matched Complex Regimens in Older HIV Patients
"Time has stood still" for many who've been on complex regimens for decades ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results